曾川锐,余家凤,刘映峰,缪绯

• 1:南方医科大学珠江医院心血管内科

摘要(Abstract)：

<正>目前,全球冠心病患病率处于持续上升阶段,占成人心血管病死亡原因的首位。据推算,中国现有冠心病患者1100万,2017年大陆地区冠心病介入治疗总例数为753 142例,较2016年增长13%[1]。自1977年实施全球第1例经皮冠状动脉腔内血管成形术(percutaneous transluminal coronary angioplasty,PTCA)以来,冠心病的介入治疗取得了许多重大进展。裸金属支架(bare-mental stent,BMS)的出现降低了PTCA后血管弹性回缩和急性闭塞的发生率[2]。随后药物洗脱支架(drugeluting stent,DES)的出现显著降低了支架内再狭窄(in-stent restenosis,ISR)的发生率,但仍存在支架内血栓形成和较长双联抗血小板治疗时间导致出血等严重并发症[3]。这些问题

关键词(KeyWords)： 药物涂层球囊;冠心病;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曾川锐,余家凤,刘映峰,缪绯

参考文献(References)：

• [1]胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要.中国循环杂志，2019,34(3):209-220.
• [2] Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents:comprehensive metaanalysis of randomized trials and observational studies.Circulation, 2009,119(25):3198-3206.
• [3] Nakazawa G, Vorpahl M, Finn AV, et al. One step forward and two steps back with drug-eluting-stents:from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.JACC Cardiovasc Imaging, 2009, 2(5):625-628.
• [4] Goldman B, Blanke H, Wolinsky H, et al. In?uence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. A new catheter approach. Atherosclerosis, 1987,65(3):215-225.
• [5] Hong MK, Wong SC, Farb A,et al. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis,1993,4(11):1023-1027.
• [6] Rasheed Q, Cacchione JG, Berry J, et al. Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. Cathet Cardiovasc Diagn,1994,31(3):240-245.
• [7] Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter:a potential drug delivery strategy following angioplasty. Am Heart J, 1991,122(4 Pt 1):1136-1140.
• [8] Wilensky RL, March KL, Gradus-Pizlo I, et al. Regional and arterial localization of radioactive microparticles af ter local delivery by unsupported or supported porous balloon catheters.Am Heart J, 1995,129(5):852-859.
• [9] Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med, 2003,349(14):1307-1309.
• [10] Heller PF. Paclitaxel and arterial smooth muscle cell proliferation.Circulation, 1998,97(16):1651.
• [11] Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis af ter coronary stent implantation. J Am Coll Cardiol, 2003,42(8):1415-1420.
• [12] Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method f or prevention and therapy of restenosis. Circulation, 2004,110(7):810-814.
• [13] Radke PW, Joner M, Joost A, et al. Vascular eff ects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model:the importance of excipients. EuroIntervention, 2011,7(6):730-737.
• [14] Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation, 2010,121(24):2672-2680.
• [15] Xu J, Hahn JY, Song YB, et al. Carina shift versus plaque shift for aggravation of side branch ostial stenosis in bifurcation lesions:volumetric intravascular ultrasound analysis of both branches. Circ Cardiovasc Interv, 2012,5(5):657-662.
• [16] Kleber FX, Schulz A, Waliszewski M, et al. Local paclitaxel induces late lumen enlargement in coronary arteries af ter balloon angioplasty. Clin Res Cardiol, 2015,104(3):217-225.
• [17] Lunardi M, Zivelonghi C, van den Brink FS, et al. Drug eluting balloon f or the treatment of patients with coronary artery disease:Current perspectives. Cardiovasc Revasc Med,2018, 19(2):215-220.
• [18] Ng VG, Mena C, Pietras C, et al. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Eur J Clin Invest,2015,45(3):333-345.
• [19] Lovich MA, Creel C, Hong K, et al. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci, 2001,90(9):1324-1335.
• [20] Axel DI, Kunert W, G?ggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 1997, 96(2):636-645.
• [21] Wiskirchen J, Sch?ber W, Schart N, et al. The effects of paclitaxel on the three phases of restenosis:smooth muscle cell proliferation, migration, and matrix formation:an in vitro study. Invest Radiol, 2004,39(9):565-571.
• [22] Posa A, Hemetsberger R, Petnehazy O, et al. Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron Artery Dis, 2008,19(4):243-247.
• [23] Rissanen TT, Uskela S, Eranen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk(DEBUT):a single-blind, randomised,non-inferiority trial. Lancet, 2019,394(10194):230-239.
• [24] Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 2006,355(20):2113-2124.
• [25] Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter. JACC Cardiovasc Interv, 2012, 5(3):323-330.
• [26] Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxelcoated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation, 2009,119(23):2986-2994.
• [27] Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxelcoated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis:the three-year results of the PEPCADⅡISR study. EuroIntervention, 2015,11(8):926-934.
• [28] Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3):a randomised, open-label trial. Lancet,2013,381(9865):461-467.
• [29] Xu B, Gao R, Wang J, et al. A prospective, multicenter,randomized trial of paclitaxel-coated balloon versus paclitaxeleluting stent for the treatment of drug-eluting stent in-stent restenosis:results f rom the PEPCAD China ISR trial. JACC Cardiovasc Interv, 2014,7(2):204-211.
• [30] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Kardiol Pol, 2018,76(12):1585-1664.
• [31] Gao L, Chen YD. Application of drug-coated balloon in coronary artery intervention:challenges and opportunities. J Geriatr Cardiol, 2016,13(11):906-913.
• [32] Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels,a prospective randomised clinical trial. The PICCOLETO study.Heart, 2010,96(16):1291-1296.
• [33] Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxeleluting stent in small coronary vessels:the BELLO(Balloon Elution and Late Loss Optimization)study. J Am Coll Cardiol, 2012,60(24):2473-2480.
• [34] Latib A, Ruparelia N, Menozzi A, et al. 3-Year follow-up of the balloon elution and late loss optimization study(BELLO). JACC Cardiovasc Interv, 2015,8(8):1132-1134.
• [35] Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease(BASKET-SMALL 2):an open-label randomised non-inferiority trial. Lancet, 2018,392(10150):849-856.
• [36] Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drugeluting stent for small-vessel disease:The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv, 2018,11(23):2381-2392.
• [37]《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识.中国介入心脏病学杂志，2016,24(2):61-67.
• [38] Lassen JF, Burzotta F, Banning AP, et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions:12th consensus document from the European Bifurcation Club.Euro Intervention, 2018,13(13):1540-1553.
• [39]付婉蓉，邱春光，卢文杰，等.药物涂层球囊在冠状动脉分叉病变中的应用现状.中国介入心脏病学杂志，2017,25(11):646-649.
• [40] Stella PR, Belkacemi A, Dubois C, et al. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus baremetal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique:six-month angiographic and12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv, 2012,80(7):1138-1146.
• [41] López Mínguez JR, Nogales Asensio JM, Doncel Vecino LJ, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bif urcated coronary lesions(BABILON trial):24-month clinical and angiographic results. EuroIntervention,2014,10(1):50-57.
• [42] Worthley S, Hendriks R, Worthley M, et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations:12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med, 2015,16(7):413-417.
• [43] Berland J, Lefèvre T, Brenot P, et al. DANUBIO-a new drugeluting balloon for the treatment of side branches in bifurcation lesions:six-month angiographic follow-up results of the DEBSIDE trial. EuroIntervention, 2015,11(8):868-876.
• [44] Loh JP, Barbash IM, Waksman R. The current status of drugcoated balloons in percutaneous coronary and peripheral interventions. EuroIntervention, 2013,9(8):979-988.
• [45] Wohrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter Cardiovasc Interv, 2013,81(5):793-799.
• [46] Onishi T, Onishi Y, Kobayashi I, et al. Drug-coated balloon angioplasty for de novo small vessel disease including chronic total occlusion and bif urcation in real-world clinical practice.Cardiovasc Interv Ther, 2019,34(2):139-148.
• [47] Tada T, Kadota K, Hosogi S, et al. Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions:a comparison with plain old balloon angioplasty.Eur Heart J Cardiovasc Imaging, 2014,15(3):307-315.
• [48] Lee JH, Jung HW, Kim JS, et al. Diff erent neointimal pattern in early vs. late in-stent restenosis and clinical outcomes after drugcoated balloon angioplasty-an optical coherence tomography study.Circ J, 2018,82(11):2745-2752.
• [49] Kawashima H, Suzuki N, Katayama T, et al. Quantified frequency-domain optical coherence tomography analysis for the thin-high signals on restenotic tissue after paclitaxel-coated balloon angioplasty. Heart Vessels, 2018,33(6):583-589.
• [50] Chung JH, Lee KE, Her AY, et al. Comparison of fractional f low reserve and angiographic characteristics af ter balloon angioplasty in de novo coronary lesions. Int J Cardiovasc Imaging, 2019, 35(11):1945-1954.